LEXX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
20.0K
0
-100.0%
174.0K
+0.0%
174.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
20.0K
0
-100.0%
174.0K
+0.0%
174.0K
Operating Expenses
2.0M
+35.5%
1.5M
-6.5%
1.6M
-45.0%
2.9M
-27.1%
3.9M
R&D
970.8K
+104.2%
475.4K
-29.2%
671.3K
-64.3%
1.9M
-30.7%
2.7M
SG&A
1.0M
+2.7%
996.5K
+10.4%
902.3K
-8.0%
980.5K
-18.8%
1.2M
Operating Income
-1993804
-37.3%
-1451903
+7.7%
-1573631
+41.5%
-2688597
+28.3%
-3750421
EBITDA
-1974596
-37.8%
-1432802
+8.0%
-1556765
+41.6%
-2667199
+28.3%
-3719466
Net Income
-1992981
-37.2%
-1452732
+9.1%
-1597503
+40.8%
-2697228
+28.8%
-3790606
EPS (Basic)
$-1.20
-33.3%
$-0.90
+14.3%
$-1.05
+49.3%
$-2.07
+34.3%
$-3.15
EPS (Diluted)
$-1.20
-33.3%
$-0.90
+14.3%
$-1.05
+49.3%
$-2.07
+34.3%
$-3.15
Shares (Diluted)
1.7M
+1.5%
1.6M
+14.4%
1.4M
+9.5%
1.3M
+6.7%
1.2M
Lexaria Bioscience (LEXX) โ€” Financials